tumor derived urinary exosomal long non coding rnas as diagnostic biomarkers for bladder cancer

• DOI: 10.17877/de290r-21723
• Publication Date: 2020-01-01
• Authors: Abbastabar, Maryam; Sarfi, Mohammad; Golestani, Abolfazl; Karimi, Ali; Pourmand, Gholamreza; Khalili, Ehsan
• Keywords: 0301 basic medicine; 0303 health sciences; Bladder cancer; 610; Urine; LncRNA; urine; 3. Good health; Exosome; 03 medical and health sciences; lncRNA; exosome; bladder cancer; Original Article; info:eu-repo/classification/ddc/610

Bladder cancer (BC) is the sixth most common malignancy in men and 17th in women. Exosomal long non-coding RNAs (lncRNAs) have been defined as a novel biomarker for BC. The aim of this study is to evaluate the clinical significance of urine exosomal PVT-1, ANRIL and PCAT-1 as a biomarker in BC patients with tumors classified as T1 or T2. Exosomes were isolated from urine of BC patients and healthy donors, then characterized according to their shape, size, and exosome markers by Electron Microscopy, Dynamic light scattering, and Western blotting. Exosomal lncRNAs extraction was done to determine the expression levels of PVT-1, ANRIL and PCAT-1 by qRT-PCR. ANRIL and PCAT-1 expression was significantly higher in BC patients compared to normal subjects. To evaluate the performance of the identified lncRNAs for BC detection, we performed ROC curves analysis. The diagnostic accuracy of ANRIL and PCAT-1, measured by AUC, was 0.7229 (sensitivity = 46.67 % and specificity = 87.5 %) and 0.7292 (sensitivity = 43.33 % and specificity = 87.5 %). Transcript levels of lncRNAs in urinary exosomes are potential diagnostic biomarkers in bladder cancer.<br/>EXCLI Journal; 19:Doc301; ISSN 1611-2156<br/>